Table 6.
Demographic and clinical characteristics of study cohorts with prescription drug coverage after matching
| AATD-COPD COHORT (CASES) | NON-AATD-COPD COHORT (CONTROLS) | |||
|---|---|---|---|---|
| N = 953 | N = 7,928 | |||
| No. of patients | (Column %) / [median] | No. of patients | (Column %) / [median] | |
| Age, mean (SD) | 56.24 (10.74) | [56] | 55.17 (9.62) | [56] |
| Age categories, n (%) | ||||
| 30 - 39 | 57 | (6) | 445 | (6) |
| 40 - 49 | 191 | (20) | 1,697 | (20) |
| 50 - 59 | 355 | (37) | 3,194 | (37) |
| 60 - 64 | 174 | (18) | 1,537 | (18) |
| >=65 | 176 | (18) | 1,055 | (18) |
| Gender, n (%) | ||||
| Male | 456 | (48) | 3,812 | (48) |
| Female | 497 | (52) | 4,116 | (52) |
| Race/Ethnicitya, n (%) | ||||
| White | 877 | (92) | 7,526 | (95) |
| African American | 39 | (4) | 201 | (3) |
| Hispanic | 33 | (3) | 195 | (2) |
| Census region, n (%) | ||||
| Northeast | 104 | (11) | 104 | (11) |
| Midwest | 287 | (30) | 287 | (30) |
| South | 414 | (43) | 414 | (43) |
| West | 148 | (16) | 148 | (16) |
| Charlson Comorbidity Scorea, n (%) | ||||
| 1 | 596 | (63) | 5,416 | (68) |
| 2 | 161 | (17) | 1,282 | (16) |
| 3 | 90 | (9) | 592 | (7) |
| 4 | 40 | (4) | 207 | (3) |
| ≥5 | 66 | (7) | 431 | (5) |
aMissing race/ethnicity was replaced using multinomial logistic regression
bQuan's Enhanced Charlson Comorbidity Score calculated within 365 days before (including) the index date